Ke Xiang Zhou
Directeur/Membre du Conseil chez BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Profil
Ke Xiang Zhou is a Non-Executive Director at Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a Director at Xiamen LP Pharmaceutical Co., Ltd., and the General Manager & Director-Equity Investment at Cmbi Capital Management Shenzhen Co. Ltd.
He was previously a Non-Executive Director at Apollomics, Inc. (United States) and a Member-Supervisory Board at Shenzhen Chipscreen Biosciences Co., Ltd.
He also served as a Director at Eucure Beijing Biopharma Co Ltd from 2018 to 2021.
Dr. Zhou received his undergraduate degree from Southern Medical University and his doctorate from Peking University Health Science Center in 1990 and 1993.
Postes actifs de Ke Xiang Zhou
| Sociétés | Poste | Début |
|---|---|---|
| BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. | Directeur/Membre du Conseil | 12/03/2018 |
| Cmbi Capital Management Shenzhen Co. Ltd. | Directeur Général | 01/12/2015 |
Xiamen LP Pharmaceutical Co., Ltd.
 Xiamen LP Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Xiamen LP Pharmaceutical Co., Ltd. engages in the development of improved new drugs. It provides perfluoropropane human albumin microspheres for injection, pramipexole hydrochloride sustained-release tablets, and clonidine hydrochloride sustained-release tablets. The company was founded by Ying Ye and Cheng Ye on November 2, 2012 and is headquartered in Xiamen, China. | Directeur/Membre du Conseil | 01/01/2018 |
Anciens postes connus de Ke Xiang Zhou
| Sociétés | Poste | Fin |
|---|---|---|
| Eucure Beijing Biopharma Co Ltd | Directeur/Membre du Conseil | 01/08/2021 |
Apollomics, Inc. (United States)
 Apollomics, Inc. (United States) BiotechnologyHealth Technology Apollomics, Inc. operates as a sciences oncology company. It is a biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company was founded by Sanjeev Gurunath Redkar and Guo-Liang Yu on May 21, 2015 and is headquartered in Foster City, CA. | Directeur/Membre du Conseil | - |
| SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. | Directeur/Membre du Conseil | - |
Formation de Ke Xiang Zhou
| Peking University Health Science Center | Doctorate Degree |
| Southern Medical University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. | Health Technology |
| BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. | Commercial Services |
| Entreprise privées | 4 |
|---|---|
Apollomics, Inc. (United States)
Apollomics, Inc. (United States) BiotechnologyHealth Technology Apollomics, Inc. operates as a sciences oncology company. It is a biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company was founded by Sanjeev Gurunath Redkar and Guo-Liang Yu on May 21, 2015 and is headquartered in Foster City, CA. | Health Technology |
| Cmbi Capital Management Shenzhen Co. Ltd. | |
Xiamen LP Pharmaceutical Co., Ltd.
Xiamen LP Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Xiamen LP Pharmaceutical Co., Ltd. engages in the development of improved new drugs. It provides perfluoropropane human albumin microspheres for injection, pramipexole hydrochloride sustained-release tablets, and clonidine hydrochloride sustained-release tablets. The company was founded by Ying Ye and Cheng Ye on November 2, 2012 and is headquartered in Xiamen, China. | Commercial Services |
| Eucure Beijing Biopharma Co Ltd |
